Angiogenesis inhibition in metastatic hormone refractory prostate cancer (HRPC): A randomized phase II trial of two doses of the matrix metalloproteinase inhibitor (MMPI) BMS-275291

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4647-4647 ◽  
Author(s):  
P. N. Lara ◽  
J. Longmate ◽  
W. Stadler ◽  
D. I. Quinn ◽  
P. Twardowski ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Matrix Metalloproteinase ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Hormone Refractory Prostate Cancer ◽  
Matrix Metalloproteinase Inhibitor ◽  
Metalloproteinase Inhibitor ◽  
Randomized Phase Ii ◽  
The Matrix ◽  
Hormone Refractory

Prednisone plus Gefitinib versus Prednisone plus Placebo in the Treatment of Hormone-Refractory Prostate Cancer: A Randomized Phase II Trial

Oncology ◽  
2008 ◽  
Vol 74 (3-4) ◽  
pp. 223-228 ◽  
Author(s):  
Francesco Boccardo ◽  
Alessandra Rubagotti ◽  
Giario Conti ◽  
Michele Battaglia ◽  
Giorgio Cruciani ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Hormone Refractory Prostate Cancer ◽  
Randomized Phase Ii ◽  
Hormone Refractory

scholarly journals A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer

2004 ◽  
Vol 10 (10) ◽  
pp. 3365-3370 ◽  
Author(s):  
Walter M. Stadler ◽  
Dingcai Cao ◽  
Nicholas J. Vogelzang ◽  
Christopher W. Ryan ◽  
Kristin Hoving ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Hormone Refractory Prostate Cancer ◽  
Antiangiogenic Agent ◽  
Randomized Phase Ii ◽  
Hormone Refractory
Sign in / Sign up

Export Citation Format

Share Document